ABCC6 deficiency and bone loss: A double benefit of etidronate for patient presenting with pseudoxanthoma elasticum?

Exp Dermatol. 2022 Oct;31(10):1635-1637. doi: 10.1111/exd.14636. Epub 2022 Jul 11.

Authors

Gilles Kauffenstein¹, Daniel Chappard², Georges Leftheriotis³, Ludovic Martin^{4

5}

Affiliations

¹ NanoRegMed - UMR INSERM 1260, Strasbourg University, Strasbourg, France.
² GEROM, Angers University, Angers, France.
³ Vascular Physiology and Medicine Unit, University Hospital of Nice, Nice, France.
⁴ PXE National Reference Center (MAGEC Nord), Angers University Hospital, Angers, France.
⁵ MITOVASC - UMR CNRS 6015 INSERM 1083, Angers University, Angers, France.

No abstract available

Keywords: ABCC6; PXE; ageing; bone loss; pyrophosphate.

Publication types

Letter

MeSH terms

Bone Diseases, Metabolic*
Etidronic Acid / therapeutic use
Humans
Multidrug Resistance-Associated Proteins / genetics
Mutation
Pseudoxanthoma Elasticum* / drug therapy
Pseudoxanthoma Elasticum* / genetics

Substances

ABCC6 protein, human
Multidrug Resistance-Associated Proteins
Etidronic Acid